Review





Similar Products

obstructive sleep apnea  (Apnimed Inc)
86
Apnimed Inc obstructive sleep apnea
Following recruitment, participants completed a screening night using an ApneaLink device after 4 days without continuous positive airway pressure (CPAP) to confirm persistent <t>obstructive</t> sleep apnoea off treatment. After screening, participants resumed CPAP for a minimum of 2 weeks before entering the interventional phase. Participants then completed three visits scheduled two weeks apart: visit 1 (V1) on usual CPAP, visit 2 (V2) after 2 weeks of CPAP withdrawal (off CPAP), and visit 3 (V3) after 2 weeks of CPAP re-initiation (on CPAP). At each visit, participants underwent ambulatory overnight respiratory polygraphy followed the next morning by standardised vascular and autonomic assessments, including brachial artery flow-mediated dilation (FMD) and spontaneous baroreflex sensitivity (BRS).
Obstructive Sleep Apnea, supplied by Apnimed Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/obstructive sleep apnea/product/Apnimed Inc
Average 86 stars, based on 1 article reviews
obstructive sleep apnea - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
obstructive pulmonary disease copd  (Wolters Kluwer Health)
86
Wolters Kluwer Health obstructive pulmonary disease copd
Following recruitment, participants completed a screening night using an ApneaLink device after 4 days without continuous positive airway pressure (CPAP) to confirm persistent <t>obstructive</t> sleep apnoea off treatment. After screening, participants resumed CPAP for a minimum of 2 weeks before entering the interventional phase. Participants then completed three visits scheduled two weeks apart: visit 1 (V1) on usual CPAP, visit 2 (V2) after 2 weeks of CPAP withdrawal (off CPAP), and visit 3 (V3) after 2 weeks of CPAP re-initiation (on CPAP). At each visit, participants underwent ambulatory overnight respiratory polygraphy followed the next morning by standardised vascular and autonomic assessments, including brachial artery flow-mediated dilation (FMD) and spontaneous baroreflex sensitivity (BRS).
Obstructive Pulmonary Disease Copd, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/obstructive pulmonary disease copd/product/Wolters Kluwer Health
Average 86 stars, based on 1 article reviews
obstructive pulmonary disease copd - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
obstructive pulmonary disease copd  (Galectin Therapeutics)
86
Galectin Therapeutics obstructive pulmonary disease copd
Following recruitment, participants completed a screening night using an ApneaLink device after 4 days without continuous positive airway pressure (CPAP) to confirm persistent <t>obstructive</t> sleep apnoea off treatment. After screening, participants resumed CPAP for a minimum of 2 weeks before entering the interventional phase. Participants then completed three visits scheduled two weeks apart: visit 1 (V1) on usual CPAP, visit 2 (V2) after 2 weeks of CPAP withdrawal (off CPAP), and visit 3 (V3) after 2 weeks of CPAP re-initiation (on CPAP). At each visit, participants underwent ambulatory overnight respiratory polygraphy followed the next morning by standardised vascular and autonomic assessments, including brachial artery flow-mediated dilation (FMD) and spontaneous baroreflex sensitivity (BRS).
Obstructive Pulmonary Disease Copd, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/obstructive pulmonary disease copd/product/Galectin Therapeutics
Average 86 stars, based on 1 article reviews
obstructive pulmonary disease copd - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
posture dependent rca obstruction 3 a synergy megatron drug  (Boston Scientific Corporation)
86
Boston Scientific Corporation posture dependent rca obstruction 3 a synergy megatron drug
Following recruitment, participants completed a screening night using an ApneaLink device after 4 days without continuous positive airway pressure (CPAP) to confirm persistent <t>obstructive</t> sleep apnoea off treatment. After screening, participants resumed CPAP for a minimum of 2 weeks before entering the interventional phase. Participants then completed three visits scheduled two weeks apart: visit 1 (V1) on usual CPAP, visit 2 (V2) after 2 weeks of CPAP withdrawal (off CPAP), and visit 3 (V3) after 2 weeks of CPAP re-initiation (on CPAP). At each visit, participants underwent ambulatory overnight respiratory polygraphy followed the next morning by standardised vascular and autonomic assessments, including brachial artery flow-mediated dilation (FMD) and spontaneous baroreflex sensitivity (BRS).
Posture Dependent Rca Obstruction 3 A Synergy Megatron Drug, supplied by Boston Scientific Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/posture dependent rca obstruction 3 a synergy megatron drug/product/Boston Scientific Corporation
Average 86 stars, based on 1 article reviews
posture dependent rca obstruction 3 a synergy megatron drug - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
biliary obstruction  (Boston Scientific Corporation)
86
Boston Scientific Corporation biliary obstruction
Abdominal contrast computed tomography revealing the tumor of the pancreatic head that caused the malignant distal biliary <t>obstruction.</t> A Axial view. B Coronal view
Biliary Obstruction, supplied by Boston Scientific Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/biliary obstruction/product/Boston Scientific Corporation
Average 86 stars, based on 1 article reviews
biliary obstruction - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
ureteral obstruction  (Boston Scientific Corporation)
86
Boston Scientific Corporation ureteral obstruction
Abdominal contrast computed tomography revealing the tumor of the pancreatic head that caused the malignant distal biliary <t>obstruction.</t> A Axial view. B Coronal view
Ureteral Obstruction, supplied by Boston Scientific Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ureteral obstruction/product/Boston Scientific Corporation
Average 86 stars, based on 1 article reviews
ureteral obstruction - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
obstructive cad  (Cleerly Inc)
86
Cleerly Inc obstructive cad
Abdominal contrast computed tomography revealing the tumor of the pancreatic head that caused the malignant distal biliary <t>obstruction.</t> A Axial view. B Coronal view
Obstructive Cad, supplied by Cleerly Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/obstructive cad/product/Cleerly Inc
Average 86 stars, based on 1 article reviews
obstructive cad - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
unau obstructive sleep apnea  (Wolters Kluwer Health)
86
Wolters Kluwer Health unau obstructive sleep apnea
Abdominal contrast computed tomography revealing the tumor of the pancreatic head that caused the malignant distal biliary <t>obstruction.</t> A Axial view. B Coronal view
Unau Obstructive Sleep Apnea, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/unau obstructive sleep apnea/product/Wolters Kluwer Health
Average 86 stars, based on 1 article reviews
unau obstructive sleep apnea - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
nephrology unilateral ureteral obstruction uuo model  (Wolters Kluwer Health)
86
Wolters Kluwer Health nephrology unilateral ureteral obstruction uuo model
Abdominal contrast computed tomography revealing the tumor of the pancreatic head that caused the malignant distal biliary <t>obstruction.</t> A Axial view. B Coronal view
Nephrology Unilateral Ureteral Obstruction Uuo Model, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nephrology unilateral ureteral obstruction uuo model/product/Wolters Kluwer Health
Average 86 stars, based on 1 article reviews
nephrology unilateral ureteral obstruction uuo model - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

Image Search Results


Following recruitment, participants completed a screening night using an ApneaLink device after 4 days without continuous positive airway pressure (CPAP) to confirm persistent obstructive sleep apnoea off treatment. After screening, participants resumed CPAP for a minimum of 2 weeks before entering the interventional phase. Participants then completed three visits scheduled two weeks apart: visit 1 (V1) on usual CPAP, visit 2 (V2) after 2 weeks of CPAP withdrawal (off CPAP), and visit 3 (V3) after 2 weeks of CPAP re-initiation (on CPAP). At each visit, participants underwent ambulatory overnight respiratory polygraphy followed the next morning by standardised vascular and autonomic assessments, including brachial artery flow-mediated dilation (FMD) and spontaneous baroreflex sensitivity (BRS).

Journal: medRxiv

Article Title: Effects of CPAP on OSA-related cardiovascular risk markers: a two-week CPAP withdrawal and re-initiation study

doi: 10.64898/2026.03.10.26348040

Figure Lengend Snippet: Following recruitment, participants completed a screening night using an ApneaLink device after 4 days without continuous positive airway pressure (CPAP) to confirm persistent obstructive sleep apnoea off treatment. After screening, participants resumed CPAP for a minimum of 2 weeks before entering the interventional phase. Participants then completed three visits scheduled two weeks apart: visit 1 (V1) on usual CPAP, visit 2 (V2) after 2 weeks of CPAP withdrawal (off CPAP), and visit 3 (V3) after 2 weeks of CPAP re-initiation (on CPAP). At each visit, participants underwent ambulatory overnight respiratory polygraphy followed the next morning by standardised vascular and autonomic assessments, including brachial artery flow-mediated dilation (FMD) and spontaneous baroreflex sensitivity (BRS).

Article Snippet: Apnimed is developing pharmacological treatments for Obstructive Sleep Apnea.

Techniques:

Patients followed at the Centre d’Investigation et de Recherche sur le Sommeil, for CPAP therapy were assessed for eligibility and included between 12 January 2024 and 12 May 2025. Included participants then underwent an ambulatory CPAP discontinuation screening period to confirm persistent obstructive sleep apnoea (OSA) off treatment. Participants with an apnoea-hypopnoea index (AHI) <15 events/h on ApneaLink™ after 4 nights without CPAP were excluded. Participants who met the screening criterion were subsequently enrolled into the interventional phase. The final analysis included those who completed all three visits with adherence to the CPAP withdrawal and re-initiation protocol.

Journal: medRxiv

Article Title: Effects of CPAP on OSA-related cardiovascular risk markers: a two-week CPAP withdrawal and re-initiation study

doi: 10.64898/2026.03.10.26348040

Figure Lengend Snippet: Patients followed at the Centre d’Investigation et de Recherche sur le Sommeil, for CPAP therapy were assessed for eligibility and included between 12 January 2024 and 12 May 2025. Included participants then underwent an ambulatory CPAP discontinuation screening period to confirm persistent obstructive sleep apnoea (OSA) off treatment. Participants with an apnoea-hypopnoea index (AHI) <15 events/h on ApneaLink™ after 4 nights without CPAP were excluded. Participants who met the screening criterion were subsequently enrolled into the interventional phase. The final analysis included those who completed all three visits with adherence to the CPAP withdrawal and re-initiation protocol.

Article Snippet: Apnimed is developing pharmacological treatments for Obstructive Sleep Apnea.

Techniques:

Abdominal contrast computed tomography revealing the tumor of the pancreatic head that caused the malignant distal biliary obstruction. A Axial view. B Coronal view

Journal: Journal of Medical Case Reports

Article Title: Successful conversion of percutaneous transhepatic gallbladder drainage to endoscopic ultrasound-guided hepaticogastrostomy combined with antegrade stenting for a malignant distal biliary obstruction due to invasive intraductal papillary mucinous carcinoma: a case report

doi: 10.1186/s13256-025-05714-0

Figure Lengend Snippet: Abdominal contrast computed tomography revealing the tumor of the pancreatic head that caused the malignant distal biliary obstruction. A Axial view. B Coronal view

Article Snippet: We then inserted a 0.025-inch guidewire (EndoSelector; Boston Scientific, MA, USA) through the FNA needle and advanced it beyond the distal biliary obstruction and major papilla to the duodenal lumen with corresponding movements of the ERCP catheter (MTW Endoskopie, Wesel, Germany).

Techniques: Computed Tomography

Conversion of percutaneous transhepatic gallbladder drainage to endoscopic ultrasound-guided hepaticogastrostomy combined with antegrade stenting. A Cholangiography through the percutaneous transhepatic gallbladder drainage catheter. B B2 intrahepatic bile duct punctured using a 19-gauge needle under endoscopic ultrasound guidance. C Guidewire advanced beyond the distal biliary obstruction and major papilla to the duodenal lumen. The location of the biliary obstruction was confirmed by a cholangiogram. The puncture tract was dilated using a drill dilator. D An uncovered metal stent placed in an antegrade manner (red arrow), and a dedicated plastic stent placed across the hepaticogastrostomy tract (yellow arrow).

Journal: Journal of Medical Case Reports

Article Title: Successful conversion of percutaneous transhepatic gallbladder drainage to endoscopic ultrasound-guided hepaticogastrostomy combined with antegrade stenting for a malignant distal biliary obstruction due to invasive intraductal papillary mucinous carcinoma: a case report

doi: 10.1186/s13256-025-05714-0

Figure Lengend Snippet: Conversion of percutaneous transhepatic gallbladder drainage to endoscopic ultrasound-guided hepaticogastrostomy combined with antegrade stenting. A Cholangiography through the percutaneous transhepatic gallbladder drainage catheter. B B2 intrahepatic bile duct punctured using a 19-gauge needle under endoscopic ultrasound guidance. C Guidewire advanced beyond the distal biliary obstruction and major papilla to the duodenal lumen. The location of the biliary obstruction was confirmed by a cholangiogram. The puncture tract was dilated using a drill dilator. D An uncovered metal stent placed in an antegrade manner (red arrow), and a dedicated plastic stent placed across the hepaticogastrostomy tract (yellow arrow).

Article Snippet: We then inserted a 0.025-inch guidewire (EndoSelector; Boston Scientific, MA, USA) through the FNA needle and advanced it beyond the distal biliary obstruction and major papilla to the duodenal lumen with corresponding movements of the ERCP catheter (MTW Endoskopie, Wesel, Germany).

Techniques: